unknown
Stage
About
EPICS Therapeutics is a clinical-stage biotechnology company developing small-molecule modulators of RNA epigenetic targets. Its lead program, EP102, is a METTL3 inhibitor currently in clinical evaluation for solid tumors.
Explore EPICS Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.